匹多莫得联合炎琥宁对难治性支原体肺炎患儿的免疫功能与临床症状的影响

Effect of pidotimod combined with Yanhuning on children with refractory Mycoplasma pneumonia clinical symptoms and immune function

目的 探讨匹多莫得联合炎琥宁治疗难治性支原体肺炎（RMPP）的临床疗效.方法 选择2013年1月-2015年1月嵊州市妇幼保健医院儿科收治的将临床确诊为RMPP的90例患儿随机分为3组,即炎琥宁组（A组）、阿奇霉素联用炎琥宁组（B组）、匹多莫得联用炎琥宁组（C组）.比较3组患儿治疗有效率、临床症状及免疫功能等指标的差异.结果 C组对免疫功能的调控作用较A组、B组更为显著,患儿预后更好,反复次数、持续时间降低（P〈0.05）.结论 匹多莫得联合炎琥宁治疗RMPP能调节患儿免疫功能,改善临床症状,应于推广.

Objective To investigate the the curative effect of pidotimod combined with Yanhuning for children with refractory mycoplasma pneumonia（RMPP）.Methods90 patients with RMPP from January 2013 to January 2015in shengzhou maternal and child health care hospital were divided into 3 groups, including Yanhuning group（A group）, azithromycin combined with Yanhuning group（B group）and pidotimod combined with Yanhuning group（C group）.And the total effective rate, the clinical symptoms, immune function parameters were analyzed.ResultsThe regulation of immune function in C group was more significant than that in A group and B group, the prognosis was better, and the repeated times and continuous time were decreased （P〈0.05）.ConclusionPidotimod combined with Yanhuning treatment of RMPP can regulate the immune function of children, improve clinical symptoms, it is worthy of popularization.